Allergan plc reached an agreement to resolve its patent litigation with Innopharma Inc. related to six patents on dry eye drug Restasis.

The patents are listed in the Orange Book and expire Aug. 27, 2024.

Under the settlement, all InnoPharma Hatch-Waxman litigation related to Restasis patents will be dismissed. Allergan will also grant InnoPharma licenses to market a generic version of Restasis in the U.S., starting Feb. 24, 2024, or earlier under certain circumstances.

In addition, under certain circumstances, the company will supply and authorize InnoPharma to launch an authorized generic version of Restasis on Aug. 28, 2024.

Additional details regarding the settlement were not disclosed.